Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators

Cancer Cell

Volumn 10, Issue 4, 2006, Pages 321-330

  Hieronymus, Haley ^a,b   Lamb, Justin ^a   Ross, Kenneth N ^a   Peng, Xiao P ^a,c   Clement, Cristina ^d   Rodina, Anna ^d   Nieto, Maria ^b   Du, Jinyan ^b   Stegmaier, Kimberly ^b   Raj, Srilakshmi M ^a,b   Maloney, Katherine N ^b   Clardy, Jon ^b   Hahn, William C ^a,b   Chiosis, Gabriela ^d   Golub, Todd R ^a,b,c  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CELLCYCLE; CHEMBIO

Indexed keywords

3 ALPHA HYDROXYDEOXODIHYDROGEDUNIN; 3 DEOXO 3BETA ACETOXYDEOXYDIHYDROGEDUNIN; 7 DESACETOXY 6,7 DEHYDROGEDUNIN; ANDROGEN RECEPTOR; BICALUTAMIDE; CELASTROL; DEACETOXY 7 OXOGEDUNIN; DEACETYLGEDUNIN; DEOXODEOXYDIHYDROGEDUNIN; DEOXYGEDUNIN; DIHYDRO 7 DESACETYLDEOXYGEDUNIN; DIHYDROCELASTROL; DIHYDROCELASTRYL DIACETATE; GEDUNIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PRISTIMEROL; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL GENETICS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRUCTURAL GENOMICS; STRUCTURE ACTIVITY RELATION;

EID: 33749433916     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.09.005     Document Type: Article

References (47)

1. Bagatell R., Beliakoff J., David C.L., Marron M.T., and Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer 113 (2005) 179-188
2. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005) 26729-26734
3. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004) 33-39
4. di Bernardo D., Thompson M.J., Gardner T.S., Chobot S.E., Eastwood E.L., Wojtovich A.P., Elliott S.J., Schaus S.E., and Collins J.J. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat. Biotechnol. 23 (2005) 377-383
5. Ebert B.L., Lee M.M., Pretz J.L., Subramanian A., Mak R., Golub T.R., and Sieff C.A. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: Identification of dexamethasone-responsive genes by microarray. Blood 105 (2005) 4620-4626
6. Febbo P.G., Lowenberg M., Thorner A.R., Brown M., Loda M., and Golub T.R. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol. 173 (2005) 1772-1777
7. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
8. Felts S.J., and Toft D.O. p23, a simple protein with complex activities. Cell Stress Chaperones 8 (2003) 108-113
9. Ficker E., Dennis A.T., Wang L., and Brown A.M. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. 92 (2003) e87-e100
10. Figueiredo J.N., Raz B., and Sequin U. Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J. Nat. Prod. 61 (1998) 718-723
11. Gardner T.S., di Bernardo D., Lorenz D., and Collins J.J. Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301 (2003) 102-105
12. Georget V., Terouanne B., Nicolas J.C., and Sultan C. Mechanism of antiandrogen action: Key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41 (2002) 11824-11831
13. Gessner P.K. Isobolographic analysis of interactions: An update on applications and utility. Toxicology 105 (1995) 161-179
14. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
15. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
16. He H., Zatorska D., Kim J., Aguirre J., Llauger L., She Y., Wu N., Immormino R.M., Gewirth D.T., and Chiosis G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 49 (2006) 381-390
17. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164 (2004) 217-227
18. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., Bennett H.A., Coffey E., Dai H., He Y.D., et al. Functional discovery via a compendium of expression profiles. Cell 102 (2000) 109-126
19. Kim J., Felts S., Llauger L., He H., Huezo H., Rosen N., and Chiosis G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen. 9 (2004) 375-381
20. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., and Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18 (2005) 601-607
21. Lam J.S., Leppert J.T., Vemulapalli S.N., Shvarts O., and Belldegrun A.S. Secondary hormonal therapy for advanced prostate cancer. J. Urol. 175 (2006) 27-34
22. Lamb J., Ramaswamy S., Ford H.L., Contreras B., Martinez R.V., Kittrell F.S., Zahnow C.A., Patterson N., Golub T.R., and Ewen M.E. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114 (2003) 323-334
23. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.-P., Subramanian A., Ross K.N., et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes and disease. Science (2006) in press
24. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61 (2001) 3550-3555
25. Llauger-Bufi L., Felts S.J., Huezo H., Rosen N., and Chiosis G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg. Med. Chem. Lett. 13 (2003) 3975-3978
26. MacKinnon S., Durst T., Arnason J.T., Angerhofer C., Pezzuto J., Sanchez-Vindas P.E., Poveda L.J., and Gbeassor M. Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives. J. Nat. Prod. 60 (1997) 336-341
27. Majumder P.K., and Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 24 (2005) 7465-7474
28. Marcu M.G., Schulte T.W., and Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 92 (2000) 242-248
29. Mimnaugh E.G., Xu W., Vos M., Yuan X., Isaacs J.S., Bisht K.S., Gius D., and Neckers L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. 3 (2004) 551-566
30. Murakami Y., Uehara Y., Yamamoto C., Fukazawa H., and Mizuno S. Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes. Exp. Cell Res. 195 (1991) 338-344
31. Padma T.V. Ayurveda. Nature 436 (2005) 486
32. Parsons A.B., Brost R.L., Ding H., Li Z., Zhang C., Sheikh B., Brown G.W., Kane P.M., Hughes T.R., and Boone C. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22 (2004) 62-69
33. Peck D., Crawford E.D., Ross K.N., Stegmaier K., Golub T.R., and Lamb J. A method for high-throughput gene expression signature analysis. Genome Biol. 7 (2006) R61
34. Reich M., Liefeld T., Gould J., Lerner J., Tamayo P., and Mesirov J.P. GenePattern 2.0. Nat. Genet. 38 (2006) 500-501
35. Soti C., Racz A., and Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 277 (2002) 7066-7075
36. Stegmaier K., Ross K.N., Colavito S.A., O'Malley S., Stockwell B.R., and Golub T.R. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat. Genet. 36 (2004) 257-263
37. Sun H., Liu X., Xiong Q., Shikano S., and Li M. Chronic inhibition of cardiac kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J. Biol. Chem. 281 (2006) 5877-5884
38. Ushiro S., Ono M., Nakayama J., Fujiwara T., Komatsu Y., Sugimachi K., and Kuwano M. New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization. Int. J. Cancer 72 (1997) 657-663
39. Vilenchik M., Solit D., Basso A., Huezo H., Lucas B., He H., Rosen N., Spampinato C., Modrich P., and Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 11 (2004) 787-797
40. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., and Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9 (1995) 401-406
41. Walsh P.C. Treatment of benign prostatic hyperplasia. N. Engl. J. Med. 335 (1996) 586-587
42. Wang J., Gines S., MacDonald M.E., and Gusella J.F. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 6 (2005) 1
43. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M., and Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11 (2005) 1088-1095
44. Westerheide S.D., Bosman J.D., Mbadugha B.N., Kawahara T.L., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., and Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 279 (2004) 56053-56060
45. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5 (2005) 761-772
46. Yang H., Chen D., Cui Q.C., Yuan X., and Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66 (2006) 4758-4765
47. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., Krogan N., Cagney G., Mai D., Greenblatt J., et al. Navigating the chaperone network: An integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120 (2005) 715-727